News & Analysis as of

Obesity Investment

Foley & Lardner LLP

GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health

Foley & Lardner LLP on

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity. At the heart of this shift is the explosive...more

Foley & Lardner LLP

Cardiology: The New Darling of Private Equity Investment

Foley & Lardner LLP on

Private equity investors are showing increased interest in the cardiology space. Why? Likely several reasons. The United States is aging, and becoming more obese, and the need for cardiologists will increase as a result. This...more

2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide